

THE LANCET

Infectious Diseases

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. *Lancet Infect Dis* 2020; published online Oct 27. [https://doi.org/10.1016/S1473-3099\(20\)30773-8](https://doi.org/10.1016/S1473-3099(20)30773-8).

APPENDIX

Table of Contents

<i>Proposed severity grading scores for SARS-CoV-2 disease</i>	<i>1</i>
<i>Key clinical outcomes for determining vaccine efficacy against COVID-19 disease(9).....</i>	<i>1</i>
<i>Obstacles to the use of SARS-CoV-2 CHIM studies to assess vaccine efficacy(10).....</i>	<i>2</i>
<i>Figure: Relationship between SARS-CoV-2 exposure, symptom onset and diagnostic windows for RT-qPCR and serology.</i>	<i>3</i>
<i>References</i>	<i>4</i>

Proposed severity grading scores for SARS-CoV-2 disease

- WHO Severity Grading(1)
- US FDA criteria(2)
- NEWS2 Score(3)
- Seven-point ordinal scale(4)
- China CDC Severity Score(5)
- NICE COVID-19 Rapid Guideline(6)
- Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment(7)
- APACHE II Score, SOFA Score, CURB65(8)

Key clinical outcomes for determining vaccine efficacy against COVID-19 disease(9)

- Rates of virologically confirmed COVID-19 disease meeting pre-specified symptoms and signs
- Rates and duration of hospitalisation
- Rates and duration of time off work
- Incidence of severe disease

APPENDIX

- Numbers of patients requiring supplemental oxygenation
- Numbers of patients requiring invasive ventilatory support
- Incidence of multi-organ dysfunction syndrome
- Mortality

Obstacles to the use of SARS-CoV-2 CHIM studies to assess vaccine efficacy(10)

- Lack of challenge agent manufactured to Good Manufacturing Practices.
- Appropriate infecting dose is unknown.
- Potential for severe disease (including death), even in young individuals, with no reliable 'rescue treatment' yet identified.
- High transmissibility of SARS-CoV-2 and risk of onward community transmission of challenge strain.
- Limited generalisability of findings to high-risk populations (e.g. elderly, immunocompromised).
- Long term sequelae of disease in survivors is unknown.

APPENDIX




Figure: Relationship between SARS-CoV-2 exposure, symptom onset and diagnostic windows for RT-qPCR and serology.

RT-qPCR positivity curves based on data presented by Zheng et al.(11) and To et al.(12)
Serology data for individuals with acquired infection adapted from Long et al.(13) and Seow et al.(14) Dashed lines represent estimates of rising qRT-PCR positivity rates in the pre-symptomatic period of infected individuals.

APPENDIX

References

1. World Health Organization. Clinical management of COVID-19: interim guidance. 2020:62.
2. U.S. Department of Health and Human Services: Food and Drug Administration. Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry. 2020.
3. Gidari A, De Socio GV, Sabbatini S, Francisci D. Predictive value of National Early Warning Score 2 (NEWS2) for intensive care unit admission in patients with SARS-CoV-2 infection. *Infectious Diseases*. 2020:1-7.
4. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. *New England Journal of Medicine*. 2020;382(19):1787-99.
5. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. 2020. Contract No.: 8.
6. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community. 2020.
7. China National Health Commission. Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition). 2020.
8. Zou X, Li S, Fang M, Hu M, Bian Y, Ling J, et al. Acute Physiology and Chronic Health Evaluation II Score as a Predictor of Hospital Mortality in Patients of Coronavirus Disease 2019. *Critical Care Medicine*. 2020;48(8).
9. CEPI COVID-19 Clinical Working Group. COVID-19 Efficacy Endpoints in Interventional Trials: What Constitutes an Incident Clinical Disease Case and What Triggers Diagnostic Work-Up. 2020.
10. World Health Organization. Feasibility, Potential Value and Limitations of Establishing a Closely Monitored Challenge Model of Experimental COVID-19 Infection and Illness in Healthy Young Adult Volunteers - Final report Draft for Public Consultation. 2020.
11. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. *BMJ*. 2020;369:m1443.
12. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *The Lancet Infectious Diseases*. 2020;20(5):565-74.
13. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med*. 2020;26(6):845-8.
14. Seow J, Graham C, Merrick B, Acors S, Steel KJA, Hemmings O, et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. *medRxiv [Preprint]*. 2020:2020.07.09.20148429.